In this issue:
Dose-escalated hydroxycarbamide for sickle cell anaemia in sub-Saharan Africa
Givosiran for acute intermittent porphyria
GRFS/CRFS outcomes after alternative donor SCT
First-line cladribine + concurrent vs. delayed rituximab in hairy cell leukaemia
Allogeneic SCT in second complete remission for core binding factor AML
Nivolumab for relapsed haematological malignancies after allogeneic SCT
Fanconi anaemia with myelodysplasia/ acute leukaemia: outcomes after allogeneic SCT
DOACs for upper extremity DVT
Antivirals increase DOAC concentrations in severe COVID-19
Rituximab/cyclophosphamide/dexamethasone for relapsed/refractory WAIHA
Please login below to download this issue (PDF)